CTOs on the Move

Ambys

www.ambys.com

 
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ambys.com
  • 131 Oyster Point Boulevard Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.481.7662

Executives

Name Title Contact Details
Alan Smith
 Chief Technology Officer Profile

Funding

Ambys raised $60M on 08/08/2018
Ambys raised $80M on 08/08/2018

Similar Companies

Genentech

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world`s leading biotech companies, with multiple products on the market and a promising development pipeline.

Enzyme by Design

A protein engineering startup passionate about developing safer cancer therapeutics

Infinity Pharmaceuticals

Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BD Biosciences

BD Biosciences is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Id Labs Inc

Id Labs Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.